Tocilizumab
- Generic Name
- Tocilizumab
- Brand Names
- Actemra, RoActemra, Tyenne, Tofidence
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 375823-41-9
- Unique Ingredient Identifier
- I031V2H011
- Background
Tocilizumab is a recombinant humanized monoclonal antibody IL-6 receptor inhibitor used to treat inflammatory and autoimmune conditions. It was first described in the literature in 2003 when Chugai, a subsidiary of Roche began developing IL-6 inhibiting monoclonal antibodies. Tocilizumab was granted FDA approval on 8 January 2010 to treat a number of inflamm...
- Indication
Tocilizumab is indicated to treat moderate to severe rheumatoid arthritis, giant cell arteritis, systemic sclerosis-associated interstitial lung disease, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, and cytokine release syndrome.
...
- Associated Conditions
- Coronavirus Disease 2019 (COVID‑19), Cytokine Release Syndrome caused by CAR-T Cell Therapy, Giant Cell Arteritis (GCA), Juvenile Chronic Polyarthritis, Moderate to Severe Rheumatoid Arthritis, Moderately to Severely Active Rheumatoid Arthritis, Polyarticular Juvenile Idiopathic Arthritis, Systemic Juvenile Idiopathic Arthritis (SJIA), Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD), Active systemic Juvenile idiopathic arthritis, Severe, active Rheumatoid arthritis
- Associated Therapies
- Monotherapy
A Study to Evaluate Tocilizumab Treatment in a Real-Life Setting
- First Posted Date
- 2012-08-14
- Last Posted Date
- 2017-07-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 151
- Registration Number
- NCT01664104
A Long-Term Extension Study of WA22762 and NA25220 of Subcutaneous (SC) Tocilizumab (TCZ) in Moderate to Severe Rheumatoid Arthritis (RA)
- First Posted Date
- 2012-08-10
- Last Posted Date
- 2016-10-12
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 218
- Registration Number
- NCT01662063
A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Severe Active Rheumatoid Arthritis, Comparing Tapering Versus Maintaining the Methotrexate Dosage
- Conditions
- Interventions
- First Posted Date
- 2012-08-09
- Last Posted Date
- 2016-10-14
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 427
- Registration Number
- NCT01661140
A Long-Term Extension Study of WA19926 on the Safety of Tocilizumab (RoActemra/Actemra) in Participants With Early Moderate to Severe Rheumatoid Arthritis
- First Posted Date
- 2012-08-01
- Last Posted Date
- 2017-01-31
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 15
- Registration Number
- NCT01655381
A Study of Tocilizumab in Participants With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Non-Biological Disease-modifying Anti-rheumatic Drugs (DMARDs)
- First Posted Date
- 2012-06-12
- Last Posted Date
- 2016-12-01
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 50
- Registration Number
- NCT01617005
Tocilizumab in the Management of Juvenile Idiopathic Arthritis Associated Uveitis
- Conditions
- Interventions
- First Posted Date
- 2012-05-22
- Last Posted Date
- 2019-01-14
- Lead Sponsor
- Eric B. Suhler
- Target Recruit Count
- 3
- Registration Number
- NCT01603355
- Locations
- 🇺🇸
Oregon Health & Science University, Portland, Oregon, United States
A Safety Study of Tocilizumab to Improve Transplant Rates in Highly Sensitized Patients Awaiting Kidney Transplantation
- Conditions
- Interventions
- First Posted Date
- 2012-05-09
- Last Posted Date
- 2016-08-25
- Lead Sponsor
- Cedars-Sinai Medical Center
- Target Recruit Count
- 10
- Registration Number
- NCT01594424
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis
- First Posted Date
- 2012-04-17
- Last Posted Date
- 2016-03-07
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 184
- Registration Number
- NCT01579006
A Non-interventional Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis
- First Posted Date
- 2012-03-23
- Last Posted Date
- 2016-11-29
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 50
- Registration Number
- NCT01562327
Tocilizumab for Treatment of Steroid Refractory Acute Graft-versus-Host Disease
- First Posted Date
- 2011-11-21
- Last Posted Date
- 2020-02-17
- Lead Sponsor
- Medical College of Wisconsin
- Target Recruit Count
- 14
- Registration Number
- NCT01475162
- Locations
- 🇺🇸
Froedtert Hospital/Medical College of Wisconsin-Clinical Cancer Center, Milwaukee, Wisconsin, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.